About: Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing
Creator	Coughlin, Melissa Baker, Susan Prabhakar, Bellur Elshabrawy, Hatem
Source	Medline; PMC
abstract	Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses.
has issue date	2012-11-21(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0050366
bibo:pmid	23185609
has license	cc-by
sha1sum (hex)	697b9d764f13648fa38faa8d93fefde6049d6517
schema:url	https://doi.org/10.1371/journal.pone.0050366
resource representing a document's title	Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing
has PubMed Central identifier	PMC3503966
has PubMed identifier	23185609
schema:publication	PLoS One
resource representing a document's body	covid:697b9d764f13648fa38faa8d93fefde6049d6517#body_text
is schema:about of	named entity 'PROTEIN ' named entity 'neutralize' named entity 'Protein' named entity 'antibodies' named entity 'Domains' named entity 'enveloped viruses' named entity 'expressing' named entity 'infected' named entity 'HIGHLY' covid:arg/697b9d764f13648fa38faa8d93fefde6049d6517 named entity 'BIND' named entity 'HR1' named entity 'TREATMENT' named entity 'DESCRIBE' named entity 'SARS' named entity 'VARIANTS' named entity 'SPIKE PROTEIN' named entity 'ATTRACTIVE' named entity 'SPECIFIC' named entity 'DOMAIN' named entity 'PASSIVE' named entity 'IMMUNE SERA' named entity 'HR2' named entity 'PROTEINS' named entity 'EFFECTIVE' named entity 'DIFFERENT' named entity 'PANEL' named entity 'HIGHLY' named entity 'SPIKE' named entity 'INFECTED' named entity 'RECEPTOR BINDING' named entity 'HR2' named entity 'CONVALESCENT' named entity 'PATIENTS' named entity 'ISOLATES' named entity 'SUITABLE' named entity 'PROTECTION' named entity 'CONSERVED' named entity 'SARS-COV' named entity 'PROTEIN ' named entity 'SUBUNIT VACCINES' named entity 'HUMAN' named entity 'USING' named entity 'SEQUENCES' named entity 'TREATMENT STRATEGY' named entity 'VIRUSES' named entity 'VIRUS' named entity 'GENERATING' named entity 'HUMAN' named entity 'HR1' named entity 'SPIKE PROTEIN' named entity 'MONOCLONAL ANTIBODIES' named entity 'THESE' named entity 'DATA' named entity 'HAVE' named entity 'REGIONS' named entity 'CITATION' named entity 'S PROTEIN' named entity 'BRITISH COLUMBIA' named entity 'NON-' named entity 'CONTAINING' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'VARIOUS' named entity 'RANGE' named entity 'CONSERVED' named entity 'SARS-COV' named entity 'BAKER' named entity 'THERAPEUTIC ANTIBODIES' named entity 'BINDING' named entity 'GLYCOPROTEIN' named entity 'MONOCLONAL ANTIBODIES' named entity '28S' named entity 'PREVIOUSLY' named entity 'ECTODOMAIN' named entity 'CLINICAL' named entity 'INC' named entity 'STUDY' named entity 'WIDE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software